quinazolines has been researched along with (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antczak, C; Bhinder, B; Calder, PA; Djaballah, H; Mahida, JP | 1 |
1 other study(ies) available for quinazolines and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
| Article | Year |
|---|---|
A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery.
Topics: Anti-Inflammatory Agents; Beclomethasone; Biosensing Techniques; Butyrophenones; Cell Line; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Flurandrenolone; High-Throughput Screening Assays; Histamine H1 Antagonists; Humans; Permeability; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Signal-To-Noise Ratio | 2012 |